Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Jack Groskopf"'
Autor:
Jeffrey J. Tosoian, Rodney L. Dunn, Yashar S. Niknafs, Anjan Saha, Randy A. Vince, Jr, Jennifer L. St. Sauver, Debra J. Jacobson, Michaela E. McGree, Javed Siddiqui, Jack Groskopf, Steven J. Jacobsen, Scott A. Tomlins, Lakshmi P. Kunju, Todd M. Morgan, Simpa S. Salami, John T. Wei, Arul M. Chinnaiyan, Aruna V. Sarma
Publikováno v:
European Urology Open Science, Vol 29, Iss , Pp 30-35 (2021)
Background: Serum prostate-specific antigen (PSA), used in prostate cancer screening, is nonspecific for cancer and is affected by age and prostate volume. More specific biomarkers could be more accurate for early detection of prostate cancer and red
Externí odkaz:
https://doaj.org/article/26c4855afa5048b6a3973d79f02797bd
Autor:
Zhuo Chen, Jielin Sun, Seong-Tae Kim, Jack Groskopf, Junjie Feng, William B. Isaacs, Roger S. Rittmaster, Lynn D. Condreay, Siqun Lilly Zheng, Jianfeng Xu
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 15, Iss 4, Pp 448-453 (2013)
Prostate cancer gene 3 (PCA3) is a non-coding gene specifically overexpressed in prostate cancer (PCa) that has great potential as a clinical biomarker for predicting prostate biopsy outcome. However, genetic determinants of PCA3 expression level rem
Externí odkaz:
https://doaj.org/article/f9b456fb2ecf49eebfaf0276c1de2be7
Autor:
Tim M. Govers, Matthew J Resnick, Ardeshir R. Rastinehad, Laura Caba, Jack Groskopf, Wim van Criekinge
Publikováno v:
World Journal of Urology, 41, 6, pp. 1527-1532
World Journal of Urology, 41, 1527-1532
World Journal of Urology, 41, 1527-1532
Purpose The health impact and cost-effectiveness of the biomarker test SelectMDx were evaluated when used in combination with MRI, in two US populations: biopsy naïve men and men with a previous negative biopsy. Methods Using a decision model, the c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e4832cd478115bf772fe54b8911975d
https://hdl.handle.net/2066/293474
https://hdl.handle.net/2066/293474
Autor:
Daniel Canter, Caroline Branch, Joao Zambon, Jack Groskopf, Aimee Foreman, Amy Lehman, Varun Sama, David Edwards, John Abran
Publikováno v:
Journal of Urology. 209
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::657b2717bc579885561cb03d396f6e9e
https://doi.org/10.1097/ju.0000000000003237.03
https://doi.org/10.1097/ju.0000000000003237.03
Autor:
Whitney Stanton, E. David Crawford, Paul Arangua, Joshua Romero, Francisco G. La Rosa, Adrie van Bokhoven, M. Scott Lucia, Paul Maroni, Wendy Poage, Jack Schalken, Fernando Kim, Jack Groskopf, Priya Werahera
Publikováno v:
Journal of Urology. 207
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f38cf2c7f1f37f8f1dcfafd8bdf19b15
https://doi.org/10.1097/ju.0000000000002611.04
https://doi.org/10.1097/ju.0000000000002611.04
Autor:
A. Collado, Augusto Wong, Jack Groskopf, Ángel Borque-Fernando, Miguel Ramírez-Backhaus, Ana Calatrava, José Antonio López-Guerrero, Jack A. Schalken, J.M. Mascarós, Carmen Mir, J. Domínguez-Escrig, Luis M. Esteban, Juan Casanova, Álvaro Gómez-Ferrer, Fuensanta Rodrigo Aragon, José Rubio-Briones, Wim Van Criekinge
Publikováno v:
Prostate, 80, 6, pp. 500-507
Prostate, 80, 500-507
Prostate, 80, 500-507
BACKGROUND A 2-gene urine-based molecular test that targets messenger RNAs known to be overexpressed in aggressive prostate cancer (PCa) has been described as a helpful method for detecting clinically significant prostate cancer (grade group [GG] ≥
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31b449be42a3d5b89e082a8a2757138c
https://doi.org/10.1002/pros.23964
https://doi.org/10.1002/pros.23964
Autor:
Nikhil Shah, Wim Van Criekinge, Kelvin A. Moses, Myron I. Murdock, Jack Groskopf, Mark Jalkut, Manuel Krispin, Robert L. Waterhouse, Michael Carter, James Sylora, Carlton Barnswell, Ronald F. Tutrone, Todd Vandenberg, Jonathan L. Silberstein, Leander Van Neste, Ronald Anglade, Zvi Shiffman
Publikováno v:
UROLOGY
OBJECTIVE: To evaluate an epigenetic assay performed on tissue from negative prostate biopsies in a group of African American (AA) men undergoing repeat biopsy, and to compare accuracy for predicting repeat biopsy outcome to prior studies conducted i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4af82ca95c4f71274a95ed9ad5c3074f
https://doi.org/10.1016/j.urology.2018.04.001
https://doi.org/10.1016/j.urology.2018.04.001
Autor:
Wim Van Criekinge, Jack Groskopf, Daphne Hessels, Geert Trooskens, Virginie Vlaeminck-Guillem, Sandra Steyaert, Jack A. Schalken, Michael K. Brawer, Alexander Haese
Publikováno v:
Journal of Urology. 201
INTRODUCTION AND OBJECTIVES:A 2-gene, urine-based molecular test that combines mRNA biomarkers with clinical factors can risk stratify patients for high-grade prostate cancer (PCa). To ensure the g...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7fa4c6044780938a17407cf5d243ba4a
https://doi.org/10.1097/01.ju.0000555629.60454.d1
https://doi.org/10.1097/01.ju.0000555629.60454.d1
Autor:
Jessica DeHart, Jack Groskopf, Karolina Grafczynska, Wim Van Criekinge, Michael K. Brawer, Elizabeth P. Garcia, Paul Yonover, Celeste Ruiz, Sandra Steyaert, Justin J. Cohen
Publikováno v:
Journal of Urology. 201
INTRODUCTION AND OBJECTIVES:There is an unmet need for methods to better identify patients most likely to benefit from repeat prostate biopsy after an initial negative biopsy. ConfirmMDx is a molec...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a4ff80f226e2e6875450c786a34951c
https://doi.org/10.1097/01.ju.0000555627.14712.18
https://doi.org/10.1097/01.ju.0000555627.14712.18
Autor:
Jason Hafron, Marshall Stein, Jack A. Schalken, Jack Groskopf, Michael K. Brawer, Kirk J. Wojno, Daphne Hessels, Wim Van Criekinge, Neal D. Shore, Jessica DeHart, Timothy Dean Langford
Publikováno v:
Urology Practice, 6, 256-260
Urology Practice, 6, 4, pp. 256-260
Urology Practice, 6, 4, pp. 256-260
Introduction:There is an unmet need for noninvasive methods to better identify patients at increased risk for clinically significant prostate cancer. SelectMDx® is a molecular urine test va...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f51fac334e0fc2d8b9922abf25c38075
https://doi.org/10.1016/j.urpr.2018.09.002
https://doi.org/10.1016/j.urpr.2018.09.002
